VivoSeq
Other

Exfoliation Syndrome

4

Pipeline Programs↗

0

Active Trials↗

3

Companies Involved↗

Exfoliation Syndrome is an early-stage landscape with 4 programs across 3 companies. The most active players are Aerie Pharmaceuticals, Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA), Novartis. 3 therapies are approved.

Intelligence

Pipeline Metrics

Competitive Density

24/100

Pipeline Velocity

0/100

Mech. Concentration

50/100

Completion Rate

100/100

Attrition Rate

0/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

A

Aerie Pharmaceuticals

1 program

Phase 2C

Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

1 program

ApprovedNovartis logo

Novartis

1 program

Approved

Pipeline

Programs by Phase

Analysis

Trial Status

3

clinical trials

Completed2 · 67%
Unknown status1 · 33%

Clinical Trials

Trial Activity

A Prospective Study to Assess the Hypotensive Efficacy of Rho-Kinase Inhibitor AR-12286 Ophthalmic Solution 0.5% and 0.7% in Patients With Exfoliation Syndrome and Ocular Hypertension or Glaucoma
Completed·RRobert Ritch, MD, LLC.·Phase 2·NCT01936389·10 enrolled
The International Collaborative Exfoliation Syndrome Treatment Study
Unknown status·TThe New York Eye & Ear Infirmary·N/A·NCT00804115·277 enrolled
Bromfenac to Reduce Inflammation in Patients With Pseudoexfoliation Syndrome After Cataract Surgery
Completed·AAzienda USL Reggio Emilia - IRCCS·Phase 4·NCT02137161·62 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)